NEW YORK, Jan 9 – Gene Logic has signed on Sumitomo Pharmaceuticals, a subsidiary of the $103 Billion trading company Sumitomo as its first Japanese customer for GeneExpress suite of databases, the companies announced Tuesday.
Under the agreement, Sumitomo will subscribe to BioExpress, which includes gene expression information from different normal and diseased tissues; and ToxExpress, which includes toxicity markers derived from animal tissues as well as human and rat cell lines. Gene Logic will also construct a customized database, integrating some of Sumitomo’s data into GeneExpress, and also implementing its GX2000 software on Sumitomo's R & D platform.
Sumitomo Pharmaceuticals will use the toxicity database to screen compounds for potential adverse effects, and will use BioExpress to facilitate drug discovery. The parties did not disclose the financial terms of the agreement.
Amersham Pharmacia Biotech K.K., which distributes Gene Logic's products in Japan, facilitated this subscription. This is the first time AP Biotech KK has procured a distribution or sales agreement for Gene Logic.
" We are pleased to be the first subscriber in Japan to Gene Logic's gene expression database which is acclaimed highly worldwide," Kikuo Ishizum, the director and General Manager of the Research Division for Sumitomo Pharmaceuticals said in a statement. " As Gene Logic and Sumitomo use the common GeneChip technology, we can integrate our data with the data from GeneExpress and utilize them together across our entire research team.”
Gene Logic recently licensed GeneExpress to IDEC Pharmaceuticals in San Diego, and has also recently procured database subscriptions from Organon, Boehringer Ingelheim Pharmaceuticals, Biogen, Proctor & Gamble,